The Nanochannel Delivery System for Constant Testosterone Replacement Therapy
dc.contributor.author | Ferrati, Silvia | en_US |
dc.contributor.author | Nicolov, Eugenia | en_US |
dc.contributor.author | Zabre, Erika | en_US |
dc.contributor.author | Geninatti, Thomas | en_US |
dc.contributor.author | Shirkey, Beverly A. | en_US |
dc.contributor.author | Hudson, Lee | en_US |
dc.contributor.author | Hosali, Sharath | en_US |
dc.contributor.author | Crawley, Michael | en_US |
dc.contributor.author | Khera, Mohit | en_US |
dc.contributor.author | Palapattu, Ganesh | en_US |
dc.contributor.author | Grattoni, Alessandro | en_US |
dc.date.accessioned | 2015-07-01T20:56:43Z | |
dc.date.available | 2016-07-05T17:27:58Z | en |
dc.date.issued | 2015-06 | en_US |
dc.identifier.citation | Ferrati, Silvia; Nicolov, Eugenia; Zabre, Erika; Geninatti, Thomas; Shirkey, Beverly A.; Hudson, Lee; Hosali, Sharath; Crawley, Michael; Khera, Mohit; Palapattu, Ganesh; Grattoni, Alessandro (2015). "The Nanochannel Delivery System for Constant Testosterone Replacement Therapy." The Journal of Sexual Medicine (6): 1375-1380. | en_US |
dc.identifier.issn | 1743-6095 | en_US |
dc.identifier.issn | 1743-6109 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/111988 | |
dc.description.abstract | IntroductionThe goal of testosterone replacement is to provide long‐term physiological supplementation at sufficient levels to mitigate the symptoms of hypogonadism.AimThe objective of this work is to determine if the implantable nanochannel delivery system (nDS) can present an alternative delivery strategy for the long‐term sustained and constant release of testosterone.MethodsA formulation of common testosterone esters (F1) was developed to enable nanochannel delivery of the low water soluble hormone. In vivo evaluation of testosterone, luteinizing hormone (LH) and follicle stimulating hormone (FSH) levels by liquid chromatography/mass spectrometry and a multiplex assay, respectively, in castrated Sprague‐Dawley rats implanted with nDS‐F1 implants or polymeric pellets was performed over a 6‐month period. The percent of testosterone concentrations observed that fell within the normal range of testosterone levels for each animal was calculated and used to compare the study groups.Main Outcome MeasuresSustain release of testosterone in vivo for over 6 months.ResultsThe subcutaneous release of F1 from nDS implants exhibited sustained in vivo release kinetics and attained stable clinically relevant plasma testosterone levels. Plasma LH and FSH levels were significantly diminished in nDS‐F1 implant–treated animals, confirming biological activity of the released testosterone.ConclusionsIn conclusion, we demonstrate that nDS‐F1 implants represents a novel approach for the treatment of male hypogonadism. Further studies will be performed in view of translating the technology to clinical use. Ferrati S, Nicolov E, Zabre E, Geninatti T, Shirkey BA, Hudson L, Hosali S, Crawley M, Khera M, Palapattu G, and Grattoni A. The nanochannel delivery system for constant testosterone replacement therapy. J Sex Med 2015;12:1375–1380. | en_US |
dc.publisher | Wiley Periodicals, Inc. | en_US |
dc.subject.other | Sustained Release | en_US |
dc.subject.other | Testosterone | en_US |
dc.subject.other | Nanochannel Implants | en_US |
dc.subject.other | Androgen Deficiency | en_US |
dc.title | The Nanochannel Delivery System for Constant Testosterone Replacement Therapy | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Urology | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/111988/1/jsm12897.pdf | |
dc.identifier.doi | 10.1111/jsm.12897 | en_US |
dc.identifier.source | The Journal of Sexual Medicine | en_US |
dc.identifier.citedreference | Grober ED, Khera M, Soni SD, Espinoza MG, Lipshultz LI. Efficacy of changing testosterone gel preparations (Androgel or Testim) among suboptimally responsive hypogonadal men. Int J Impot Res 2008; 20: 213 – 217. | en_US |
dc.identifier.citedreference | Mulligan T, Frick MF, Zuraw QC, Stemhagen A, McWhirter C. Prevalence of hypogonadism in males aged at least 45 years: The HIM study. Int J Clin Pract 2006; 60: 762 – 769. | en_US |
dc.identifier.citedreference | Ferrati S, Fine D, You J, De Rosa E, Hudson L, Zabre E, Hosali S, Zhang L, Hickman C, Sunder Bansal S, Cordero‐Reyes AM, Geninatti T, Sih J, Goodall R, Palapattu G, Kloc M, Ghobrial RM, Ferrari M, Grattoni A. Leveraging nanochannels for universal, zero‐order drug delivery in vivo. J Control Release 2013; 172: 1011 – 1019. | en_US |
dc.identifier.citedreference | Yassin AA, Haffejee M. Testosterone depot injection in male hypogonadism: A critical appraisal. Clin Interv Aging 2007; 2: 577 – 590. | en_US |
dc.identifier.citedreference | McCullough AR, Khera M, Goldstein I, Hellstrom WJ, Morgentaler A, Levine LA. A multi‐institutional observational study of testosterone levels after testosterone pellet (Testopel((R))) insertion. J Sex Med 2012; 9: 594 – 601. | en_US |
dc.identifier.citedreference | Daniell HW, Lentz R, Mazer NA. Open‐label pilot study of testosterone patch therapy in men with opioid‐induced androgen deficiency. J Pain 2006; 7: 200 – 210. | en_US |
dc.identifier.citedreference | Kumar P, Kumar N, Thakur DS, Patidar A. Male hypogonadism: Symptoms and treatment. J Adv Pharm Technol Res 2010; 1: 297 – 301. | en_US |
dc.identifier.citedreference | Bruno G, Geninatti T, Hood RL, Fine D, Scorrano G, Schmulen J, et al. Leveraging electrokinetics for the active control of dendritic fullerene‐1 release across a nanochannel membrane. Nanoscale 2015; 7: 5240 – 5248. | en_US |
dc.identifier.citedreference | Farra R, Sheppard NF Jr, McCabe L, Neer RM, Anderson JM, Santini JT Jr, et al. First‐in‐human testing of a wirelessly controlled drug delivery microchip. Sci Transl Med 2012; 4: 122ra21. | en_US |
dc.identifier.citedreference | Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, et al. Testosterone therapy in men with androgen deficiency syndromes: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010; 95: 2536 – 2559. | en_US |
dc.identifier.citedreference | Lodhi GM, Hameed W, Ahmed T, Latif R, Aslam M. Effects of ascorbic acid & alpha tocopherol supplementation on basal testosterone cortisol ratio in male Sprague Dawley rats. Pak J Physiol 2011; 7: 7 – 10. | en_US |
dc.identifier.citedreference | Meo SA, Al‐Drees AM, Husain S, Khan MM, Imran MB. Effects of mobile phone radiation on serum testosterone in Wistar albino rats. Saudi Med J 2010; 31: 869 – 873. | en_US |
dc.identifier.citedreference | Ferrati S, Nicolov E, Bansal S, Zabre E, Geninatti T, Ziemys A, Hudson L, Ferrari M, Goodall R, Khera M, Palapattu G, Grattoni A. Delivering enhanced testosterone replacement therapy through nanochannels. Adv Healthc Mater 2015; 4: 446 – 451. | en_US |
dc.identifier.citedreference | Ferrati S, Fine D, You J, De Rosa E, Hudson L, Zabre E, et al. Leveraging nanochannels for universal, zero‐order drug delivery in vivo. J Control Release 2013; 172: 1011 – 1019. | en_US |
dc.identifier.citedreference | Grattoni A, Gill J, Zabre E, Fine D, Hussain F, Ferrari M. Device for rapid and agile measurement of diffusivity in micro‐ and nanochannels. Anal Chem 2011; 83: 3096 – 3103. | en_US |
dc.identifier.citedreference | Grattoni A, Fine D, Zabre E, Ziemys A, Gill J, Mackeyev Y, et al. Gated and near‐surface diffusion of charged fullerenes in nanochannels. ACS Nano 2011; 5: 9382 – 9391. | en_US |
dc.identifier.citedreference | Fine D, Grattoni A, Hosali S, Ziemys A, De Rosa E, Gill J, et al. A robust nanofluidic membrane with tunable zero‐order release for implantable dose specific drug delivery. Lab Chip 2010; 10: 3074 – 3083. | en_US |
dc.identifier.citedreference | Celia C, Ferrati S, Bansal S, van de Ven AL, Ruozi B, Zabre E, et al. Sustained zero‐order release of intact ultra‐stable drug‐loaded liposomes from an implantable nanochannel delivery system. Adv healthc Mater 2014; 3: 230 – 238. | en_US |
dc.identifier.citedreference | Sih J, Bansal SS, Filipini S, Ferrati S, Raghuwansi K, Zabre E, et al. Characterization of nanochannel delivery membrane systems for the sustained release of resveratrol and atorvastatin: New perspectives on promoting heart health. Anal Bioanal Chem 2013; 405: 1547 – 1557. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.